These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 19576880)

  • 1. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.
    Fodero-Tavoletti MT; Smith DP; McLean CA; Adlard PA; Barnham KJ; Foster LE; Leone L; Perez K; Cortés M; Culvenor JG; Li QX; Laughton KM; Rowe CC; Masters CL; Cappai R; Villemagne VL
    J Neurosci; 2007 Sep; 27(39):10365-71. PubMed ID: 17898208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein, Abeta and Alzheimer's disease.
    Wirths O; Bayer TA
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.
    Obi K; Akiyama H; Kondo H; Shimomura Y; Hasegawa M; Iwatsubo T; Mizuno Y; Mochizuki H
    Exp Neurol; 2008 Apr; 210(2):409-20. PubMed ID: 18164295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
    Beyer K; Domingo-Sàbat M; Santos C; Tolosa E; Ferrer I; Ariza A
    Brain; 2010 Dec; 133(Pt 12):3724-33. PubMed ID: 20959308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
    Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
    Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
    Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
    Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain.
    Ye L; Velasco A; Fraser G; Beach TG; Sue L; Osredkar T; Libri V; Spillantini MG; Goedert M; Lockhart A
    J Neurochem; 2008 May; 105(4):1428-37. PubMed ID: 18221373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects.
    Aho L; Parkkinen L; Pirttila T; Alafuzoff I
    Dement Geriatr Cogn Disord; 2008; 25(5):423-32. PubMed ID: 18391488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells.
    Kazmierczak A; Strosznajder JB; Adamczyk A
    Neurochem Int; 2008 Dec; 53(6-8):263-9. PubMed ID: 18804502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene.
    Yamaguchi K; Cochran EJ; Murrell JR; Polymeropoulos MH; Shannon KM; Crowther RA; Goedert M; Ghetti B
    Acta Neuropathol; 2005 Sep; 110(3):298-305. PubMed ID: 15981014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
    Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
    Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.
    Deramecourt V; Bombois S; Maurage CA; Ghestem A; Drobecq H; Vanmechelen E; Lebert F; Pasquier F; Delacourte A
    J Neuropathol Exp Neurol; 2006 Mar; 65(3):278-88. PubMed ID: 16651889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
    Serdons K; Verduyckt T; Vanderghinste D; Borghgraef P; Cleynhens J; Van Leuven F; Kung H; Bormans G; Verbruggen A
    Eur J Med Chem; 2009 Apr; 44(4):1415-26. PubMed ID: 18992967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.